Inotiv
NOTV
About: Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Employees: 2,075
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
9% more funds holding
Funds holding: 68 [Q1] → 74 (+6) [Q2]
5% more call options, than puts
Call options by funds: $300K | Put options by funds: $286K
0.61% more ownership
Funds ownership: 23.89% [Q1] → 24.5% (+0.61%) [Q2]
5% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 19
14% less capital invested
Capital invested by funds: $17.9M [Q1] → $15.3M (-$2.55M) [Q2]
Financial journalist opinion
